BioLife Solutions Inc
NASDAQ:BLFS

Watchlist Manager
BioLife Solutions Inc Logo
BioLife Solutions Inc
NASDAQ:BLFS
Watchlist
Price: 27.39 USD 4.9% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
BioLife Solutions Inc?
Write Note

BioLife Solutions Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioLife Solutions Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
BioLife Solutions Inc
NASDAQ:BLFS
Accounts Receivables
$17.9m
CAGR 3-Years
-4%
CAGR 5-Years
33%
CAGR 10-Years
36%
Haemonetics Corp
NYSE:HAE
Accounts Receivables
$213.5m
CAGR 3-Years
15%
CAGR 5-Years
4%
CAGR 10-Years
4%
ICU Medical Inc
NASDAQ:ICUI
Accounts Receivables
$174m
CAGR 3-Years
14%
CAGR 5-Years
-4%
CAGR 10-Years
17%
Align Technology Inc
NASDAQ:ALGN
Accounts Receivables
$1B
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
23%
Lantheus Holdings Inc
NASDAQ:LNTH
Accounts Receivables
$329.3m
CAGR 3-Years
73%
CAGR 5-Years
52%
CAGR 10-Years
23%
Merit Medical Systems Inc
NASDAQ:MMSI
Accounts Receivables
$189.8m
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
11%
No Stocks Found

BioLife Solutions Inc
Glance View

Market Cap
1.3B USD
Industry
Health Care

BioLife Solutions Inc., hailing from Bothell, Washington, tells a story of innovation within the niche yet critical biopreservation industry. Emerging as a vital player for cell and gene therapy developers, BioLife Solutions specializes in creating hypothermic storage and transport media tailored for fragile biologic material. Their cornerstone products, like CryoStor and HypoThermosol, are formulated to prolong the shelf-life and viability of cells, tissues, and organs during storage and transportation. These solutions are designed for ultra-cold environments, ensuring the cellular integrity required by biopharmaceutical companies and research institutions engaged in the leading-edge development of regenerative medicine. The company's business model is centered around both direct sales and strategic partnerships. By deeply embedding its proprietary preservation media into clinical-grade processes, BioLife Solutions establishes itself as an integral component of its clients' supply chains. In doing so, the company generates revenue not just from initial sales of its products, but from ongoing usage as therapies move through development pipelines into mainstream clinical applications. Additionally, their diversification into automated thawing devices and personalized medicine services bolster recurring revenue streams, positioning them strategically in an expanding market driven by technological advancements in cellular therapies. Thus, BioLife Solutions stands firmly at the confluence of innovation and necessity, drawing strength from its strategic foresight and commitment to preserving the future of medicine.

BLFS Intrinsic Value
6.98 USD
Overvaluation 75%
Intrinsic Value
Price

See Also

What is BioLife Solutions Inc's Accounts Receivables?
Accounts Receivables
17.9m USD

Based on the financial report for Sep 30, 2024, BioLife Solutions Inc's Accounts Receivables amounts to 17.9m USD.

What is BioLife Solutions Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
36%

Over the last year, the Accounts Receivables growth was -27%. The average annual Accounts Receivables growth rates for BioLife Solutions Inc have been -4% over the past three years , 33% over the past five years , and 36% over the past ten years .

Back to Top